Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

GARDP: An innovative public health approach to counter AMR

Webinar

07.12.2023

Fixing the AMR pipeline isn’t just about developing new treatments. To stand strong against AMR we need to put public health needs at the center of antibiotic drug development. Current antibiotics are not reaching people who need them and new ones aren’t being developed where they are most needed.

The webinar will be an opportunity to not only present GARDP’s new five-year strategy, but also highlight our achievements over the past five years in developing new and improved treatments for drug-resistant infections, including neonatal sepsis, serious bacterial infections and gonorrhoea, and ensure that they reach the people who need them most, including children, women and the elderly.

Over the past five years, through our partnership model, GARDP has successfully developed a comprehensive portfolio of antibiotic treatments and we are well on our way of reaching our goal of delivering five treatments by 2025 (with four treatments in our current portfolio). We are also pioneering new access models with our innovator, manufacturing and distribution partners.

Our unique not-for-profit antibiotic R&D model focuses on integrating R&D and access, negotiating public-private collaboration and licensing agreements, and working in partnership with all key stakeholders—including scientists, clinicians, industry, manufacturers, regulators, donors and civil society—to coordinate efforts in the antibiotic pipeline of drug development and access with the goal of addressing public health needs.

Our new five-year strategy outlines how GARDP is a global solution to AMR, working with partners to create a new global antibiotic pipeline that is driven by public health need rather than profit.

 

Speakers:

  • Manica Balasegaram, Executive Director, GARDP
  • Angela Dramowski, Professor of Paediatric Infectious Diseases at Tygerberg Hospital, Stellenbosch University; Principal Investigator of the neonatal sepsis observational study
  • Ramanan Laxminarayan, One Health Trust Founder and Director; GARDP Board Chair
  • Veronika von Messling, Director-General for Life Sciences at the German Federal Ministry of Education and Research; GARDP Board Member
  • Jasper Claessen, Senior Advisor at the Department of Pharmaceutical Affairs, Dutch Ministry of Health

Moderator: Laura Piddock, Scientific Director, GARDP